Januvia and Janumet are Merck & Co.’s (MRK) blockbuster diabetes drugs. They're are used to lower blood sugar levels in patients with Type 2 diabetes.

Januvia (sitagliptin) is a prescription drug that’s used to treat type 2 diabetes. This drug can interact with other medications. For example, Januvia can interact with other diabetes medications and ...

Januvia (sitagliptin) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to manage blood sugar levels in adults with type 2 diabetes, along with changes in ...

The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions. An evaluation of results ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...

Sitagliptin (JANUVIA tab) is indicated to improve glucose control in adults with type 2 diabetes mellitus along with diet and exercise. The information provided on this page is intended to serve as a ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

Merck said Thursday it closed out the fourth quarter of 2011 with $12.3 billion in sales, a 2% increase from $12 billion in the same period in 2010. While that missed the Street’s consensus for the ...

If you take Eliquis, Januvia, or one of eight other widely prescribed brand-name drugs, your Medicare Part D plan started paying a different price for it on January 1, 2026. The list price the federal ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

Merck's first-quarter earnings are a big disappointment. Technically, earnings per share of $0.85 beat analyst forecasts by six cents due to one-time tax benefit. Meanwhile overall sales of $10.7 ...